You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

New Four-In-One Anti-HIV Drug

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000423499.30770.fe
Drug Watch
Abstract

* Stribild, a new combination anti-HIV drug, has been approved by the Food and Drug Administration. The product contains two new drugs, elvitegravir and cobicistat, and two previously approved drugs, emtricitabine and tenofovir.

* Given once daily to treatment-naïve patients with HIV-1, Stribild is considered a complete treatment for HIV. This decreases the pill burden and should aid in promoting treatment adherence.

* Stribild's label carries boxed warnings similar to the labels of some other HIV drugs.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: daschen1@jhu.com.

© 2012 Lippincott Williams & Wilkins, Inc.